SCHEMBL581282

SCHEMBL581282

COC(=O)N1CCC(C(=O)O)CC1Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 7/20 0.46
NOTUM Q6P988 1/20 0.44
CYP3A4 P08684 2/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
KCNH2 Q12809 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
KMT2A Q03164 1/20 0.39
OPRD1 P41143 1/20 0.39
SIGMAR1 Q99720 2/20 0.38
SLC6A5 Q9Y345 1/20 0.38
PRKAB2 O43741 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38
PRKAB1 Q9Y478 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL581526 1.00 TACR1 (0.46) TACR1NOTUMCYP3A4MAPTMAPK1
SCHEMBL581527 1.00 TACR1 (0.46) TACR1NOTUMCYP3A4MAPTMAPK1
SCHEMBL581783 1.00 TACR1 (0.46) TACR1NOTUMCYP3A4MAPTMAPK1
SCHEMBL587559 0.96 TACR1 (0.43) TACR1NOTUMCYP3A4MAPTMAPK1
SCHEMBL586823 0.91 TACR1 (0.44) TACR1CYP3A4MAPTMAPK1KCNH2
SCHEMBL581238 0.90 NPC1 (0.41) TACR1CYP3A4MAPK1KMT2A
SCHEMBL580834 0.87 NOTUM (0.41) NOTUMCYP3A4MAPTKMT2A
SCHEMBL581110 0.87 TACR1 (0.48) TACR1NOTUMHRH3KMT2ASIGMAR1
SCHEMBL581462 0.87 NOTUM (0.49) TACR1NOTUMKCNH2HRH3OPRD1
SCHEMBL581415 0.87 NOTUM (0.43) TACR1NOTUMCYP3A4HRH3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459246-B Isoxazol-3 (2H) -one analogs as therapeutic agents ASTRAZENECA AB 2014-05-07 CN disclosed
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US disclosed
CN-102459246-A Isoxazol-3 (2H) -one analogs as therapeutic agents ASTRAZENECA AB 2012-05-16 CN disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 TACR1 474/4885NOTUM 2559/4885CYP3A4 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.